Cizzle Bio launches CIZ1B lung cancer blood test in limited Texas commercial rollout
Cizzle Bio launches CIZ1B in Texas as a lung cancer blood test, with wider adoption hinging on clinical validation and reimbursement.
Medical Devices & Diagnostics
Pharma & Biotech
Why Royalty Pharma is betting up to $425m on Neurimmune’s Phase 3 heart drug
Neurimmune sells part of its cliramitug royalty to Royalty Pharma for up to $425 million as the ATTR-CM antibody advances through Phase 3.
Medical Devices & Diagnostics
CONMED’s AirSeal gains a crucial da Vinci 5 fit, but will hospitals change their robotic workflow?
See how CONMED’s AirSeal expansion to da Vinci 5 hex cannulas could influence robotic surgery workflows, adoption and recurring sales.
Pharma & Biotech
Can BostonGene’s AI reveal which gastrointestinal cancer patients will benefit from ICI-PDT therapy?
BostonGene and Kyoto University will use multiomic AI to seek response biomarkers in a Phase II ICI-PDT trial for advanced GI cancers.
Medical Devices & Diagnostics
Johnson & Johnson has entered soft-tissue robotics, but can Ottava loosen da Vinci’s grip?
Johnson & Johnson can launch its table-integrated Ottava surgical robot in the United States, opening a new competitive front against Intuitive Surgical and Medtronic.
Pharma & Biotech
Summit Therapeutics nears FDA decision with stronger ivonescimab survival signal
Ivonescimab’s updated HARMONi survival trend strengthens before the FDA’s November decision, but key statistical details remain undisclosed.
Medical Devices & Diagnostics
How Science Corporation’s PRIMA system restores prosthetic central vision in advanced AMD
Science Corporation launches CE-marked PRIMA in Europe, but reimbursement, specialist training and real-world outcomes will determine access.
Pharma & Biotech
Signatera detected 90% of recurrences versus 55% for AMERK. Is Merkel cell surveillance about to change?
Signatera showed 90% sensitivity versus 55% for AMERK in Merkel cell carcinoma, strengthening Natera’s case for broader MRD surveillance.
Medical Devices & Diagnostics
Demetra wants to move beyond implants. Can Masmec Biomed help build its surgical technology ecosystem?
Demetra and Masmec Biomed target AI, surgical navigation and robotics, but product scope, regulatory plans and timelines remain undisclosed.
Pharma & Biotech
D&D Pharmatech’s MASH candidate gains credibility as Phase 2 findings enter peer review
Peer-reviewed Phase 2 data link zabopegdutide to rapid liver fat and stiffness reductions, while Phase 3 validation remains the decisive test.